Evidence map›Paper›PMID 42411936›Full record

ArticleInternal medicine journal2026

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio and 18 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Sean McKeague *Department of Haematology and Bone Marrow Transplantation, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-3280-0120
Joanna Katarzyna Czerwinski *Department of Haematology, SA Pathology and SA Health, Frome Road, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-2599-8407
Xavier BadouxDepartment of Haematology, NSW Health Pathology, St George Hospital, Sydney, New South Wales, Australia.
Rory BennettDepartment of Haematology, North Shore Hospital, Auckland, New Zealand.ORCID https://orcid.org/0000-0003-4037-4536
Giles BestFlinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0003-2685-3880
Nicole ChiaGenomic Diagnostics, Healius Pathology, Sydney, New South Wales, Australia.
Tara CochraneDepartment of Haematology, Gold Coast University Hospital, Gold Coast, Queensland, Australia.ORCID https://orcid.org/0000-0002-2668-1399
Kyle CrassiniDepartment of Haematology, Mid North Coast Local Health District, Coffs Harbour, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3785-2931
Gavin CullDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Pietro Di CiaccioDepartment of Haematology, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.ORCID https://orcid.org/0000-0002-9282-8619
Pasquale FedeleLymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-2008-9749
Rosemary HarrupDepartment of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.ORCID https://orcid.org/0000-0002-9770-2791
Sharon JacksonDepartment of Haematology, Middlemore Hospital, Auckland, New Zealand.
Bryone KussGenetics and Molecular Medicine, Flinders University, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-5811-1331
Masa LasicaDepartment of Clinical Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-7971-4003
Denise LeeDepartment of Clinical Haematology, Austin Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0009-0003-0096-7764
Thomas LewDepartment of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Paula MarltonDepartment of Haematology, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
Monique Menzies WojtowiczDepartment of Haematology, Macquarie University Hospital, Macquarie University and Scientia Clinical Research, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7063-3562
Stephen OpatLymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0308-6458
Sumita RatnasingamDepartment of Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0932-5712
John Francis SeymourDepartment of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-2188-6835
Dipti TalaulikarCanberra Health Services, Canberra, Australian Capital Territory, Australia.ORCID https://orcid.org/0000-0001-6766-8345
Constantine Si Lun TamMonash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-9759-5017
Robert WeinkoveDepartment of Haematology, Wellington Hospital, Wellington, New Zealand.ORCID https://orcid.org/0000-0003-3645-7988
Joel WightDepartment of Haematology, Townsville University Hospital, Townsville, Queensland, Australia.ORCID https://orcid.org/0000-0002-3216-2392
Stephen Mulligan *Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1928-2098
Mary Ann Anderson *Department of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-3515-0215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management. This paper provides an expert consensus update to the 2023 statement, offering current, regionally relevant guidance on the diagnosis, risk stratification and management of CLL, including treatment selection, sequencing of therapy, management of complications and supportive care. Recommendations were developed through a structured consensus process involving Australian and New Zealand clinicians with expertise in CLL and are endorsed by the Australasian Lymphoma Alliance, the Australasian Leukaemia and Lymphoma Group CLL Working Party and the Haematology Society of Australia and New Zealand. Levels of evidence and grades of recommendation were assigned using the Grading of Recommendations Assessment, Development and Evaluation framework.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAustralasiaAustraliaHumansNew ZealandBCL2 inhibitorsBTK inhibitorsChronic Lymphocytic LeukaemiaCLLConsensus guidelineSmall lymphocytic lymphoma

Identifiers

PMID42411936
PMCPMC13458224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.